Clinical trial
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic…
NCT00416793 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00416793 |
|---|---|
| Title | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer |
| Official title | A Phase II Study of Bortezomib in Combination With Carboplatin in Patients With Metastatic Pancreatic Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer |
| Intervention type | Drug, Other |
| Interventions | bortezomib, carboplatin, laboratory biomarker analysis |
| Enrollment | 9 |
| Start date | Dec 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Dec 28, 2006 |
| Last update posted | Oct 31, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: